Leukemia, Chronic Myeloid Clinical Trial
Official title:
A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Who Have Achieved a Complete Hematologic Remission, Complete Cytogenetic Remission, and Major Molecular Remission, But Not a Complete Molecular Remission on a Tyrosine Kinase Inhibitor Alone.
This study combines two drugs (ruxolitinib and the tyrosine kinase inhibitor, nilotinib) in an attempt to eliminate the CML (Chronic Myeloid Leukemia) stem cell population and thus allow for the deepest and most durable response possible in patients with CML in chronic phase who have achieved a complete hematologic remission (CHR), complete cytogenetic remission (CCyR), and major molecular remission (MMR), but not a complete molecular remission (CMR). The study will look at safety and tolerability of ruxolitinib when combined with nilotinib in a phase I study and will help establish the MTD (Maximum Tolerated Dose) of ruxolitinib when combined with nilotinib. Once the optimal dose of ruxolitinib is established in the phase I setting, a phase II evaluation will seek to establish the efficacy of this combination.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384848 -
The EMPATHY Pilot Study
|
N/A | |
Recruiting |
NCT03515018 -
Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients
|
Phase 3 | |
Active, not recruiting |
NCT02381379 -
Malaysia Stop Tyrosine Kinase Inhibitor Trial
|
Phase 3 | |
Active, not recruiting |
NCT02852486 -
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response
|
Phase 2 | |
Recruiting |
NCT02326311 -
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
|
Phase 3 | |
Terminated |
NCT02627573 -
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
|
Phase 2 | |
Terminated |
NCT01761695 -
Chronic Myelod Leukemia Registry at Asan Medical Center
|
||
Not yet recruiting |
NCT02389920 -
Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
|
Phase 4 |